Last summer, Chinese prosecutors sentenced Peter Humphrey--a private eye linked to GlaxoSmithKline's 2013 bribery scandal--to 2.5 years in prison. But now, after serving about two years, he's been released.
Just weeks after AstraZeneca said it would build a new facility in Sweden where it intends to fill and package biologics, the U.K. drugmaker said it was doing something more traditional in Algeria. Through a joint venture there, it will build a $125 million small-molecule plant.
Quintiles has opened up a new, up-sized headquarters in China, toasting the country's growth as a global biopharma power and angling to play a bigger role in its continued evolution.
China has steeply raised the fees it requires to submit a medical device or a drug to the China Food and Drug Administration to more than $100,000. The move is expected to provide better funding for the regulator, which is struggling with a huge backlog of products awaiting approval.
German pharmaceutical giant Bayer said it expects to spend $3.4 million to expand its Indonesian production capacity for effervescents this year.
Quintiles, the world's largest CRO, is targeting the growing number of small and midsize biotech companies in Asia, porting its bespoke offering to the region in hopes of partnering with the continent's up-and-coming drug developers.
Medtronic CEO Omar Ishrak has long turned to emerging markets as a potential growth driver, and tapping into India's burgeoning population will play a key role in ramping up the company's business there, he said.
A joint venture between Malaysia's Pharmaniaga and Saudi Arabia-based Modern Healthcare Solutions to build a pharma plant in Saudi Arabia appears unlikely to make it to the finish line.
Biocon, India's pre-eminent biotech company, is planning to spin out its in-house CRO in an Indian IPO, a move that shines a light on the country's evolving industry.
China is looking inward to chart growth for its device sector, laying out guidelines to spur local innovation and move away from global imports. Now, the country is going after three med tech multinationals, launching a probe to investigate suspected bribery by some of the industry's top players.